| 19.9 -0.53 (-2.59%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.52 | 1-year : | 28.97 |
| Resists | First : | 21.85 | Second : | 24.8 |
| Pivot price | 21.77 |
|||
| Supports | First : | 17.06 | Second : | 14.2 |
| MAs | MA(5) : | 20.85 |
MA(20) : | 22.1 |
| MA(100) : | 18.18 |
MA(250) : | 18.68  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 6.2 |
D(3) : | 8.9 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 29.64 | Low : | 11.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TNDM ] has closed above bottom band by 6.0%. Bollinger Bands are 22.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.39 - 20.53 | 20.53 - 20.64 |
| Low: | 19.11 - 19.3 | 19.3 - 19.44 |
| Close: | 19.73 - 19.99 | 19.99 - 20.19 |
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Wed, 02 Sep 2026
A Look at Tandem Diabetes Care Inc (TNDM) After 3.4% Decline -- GF Value $24.05 vs Price $20.56 - GuruFocus
Tue, 18 Aug 2026
Tandem Diabetes (NASDAQ: TNDM) exec nets 475 shares after RSU vesting - Stock Titan
Tue, 18 Aug 2026
Tandem Diabetes (NASDAQ: TNDM) EVP issued 2,827 shares, 809 withheld - Stock Titan
Mon, 17 Aug 2026
Is Tandem Diabetes Care (TNDM) Undervalued Following Q2 Earnings And Reaffirmed Guidance? - simplywall.st
Thu, 06 Aug 2026
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results - Business Wire
Thu, 06 Aug 2026
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 70 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 115.7 (%) |
| Shares Short | 11,240 (K) |
| Shares Short P.Month | 12,730 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.87 |
| Profit Margin | -6.1 % |
| Operating Margin | -5.5 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -48.1 % |
| Qtrly Rev. Growth | 5.8 % |
| Gross Profit (p.s.) | 8.38 |
| Sales Per Share | 14.94 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -22.23 |
| PEG Ratio | 0 |
| Price to Book value | 10.63 |
| Price to Sales | 1.33 |
| Price to Cash Flow | -252.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|